The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients. Randomized Intervention Trial With a Medical Device (Acetium®Capsules)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Biohit Oyj
- 入组人数
- 200
- 试验地点
- 7
- 主要终点
- Number of migraine attacks (NMA) per evaluation interval
研究概览
简要总结
The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort) the headache attacks in migraine patients.
详细描述
Background: Globally, 15% of the population is affected by migraines at some point in their life-time. Pprophylactic treatment of migraines is an important part of the total management of migraine patients, having twofold goals: i) to reduce the frequency, painfulness, and/or duration of migraines, and ii) to increase the effectiveness of abortive therapy. During the past several decades, a large number of optional modalities have been tested as preventive measures of migraine attacks. Not unexpectedly, the effects of any such preventive therapies are highly variable, and in many patients, the attack frequency is not under satisfactory control. Many of these drugs also have untoward side effects that offset their potential benefits.
Recently, spontaneous case testimonials were received by Biohit Oyj from migraine patients, reporting that our new medical device, Acetium™ capsule (containing 100mg L-cysteine, developed for inactivation of acetaldehyde in the stomach contents after alcohol intake), proved to be highly effective against migraine attacks. Their headache attacks disappeared almost immediately after onset of L-cysteine administration, all of them remaining in complete remission for several months up to several years by now.
These spontaneous testimonials prompted us to formulate a novel study hypothesis that could possibly explain these dramatic effects of L-cysteine in migraine prevention, to be tested in this RCT. This novel hypothesis is starting from the fact that, swelling and dilatation of cerebral blood vessels is necessary to provoke the attack in this vascular-type of headache.
It is known that Nitric Oxide (NO) is the final trigger of migraine attack, operating through phosphorylated protein kinase G (PKG) and Ca2+ channels, slowing the influx of calcium into the cell, which leads to smooth muscle relaxation and vasodilation. Histamine is a potent inducer of NO Synthase, making NO available locally on the vasculature, acting through endothelial H1-receptors. Histamine is synthesized from histidine in tissue mast cells, which are ubiquitous cells and their activation e.g. in the meninges has long been suspected to be involved in generating migraine headaches. Finally, one of the potent liberators of histamine from the mast cells is acetaldehyde, which, in turn, is effectively inactivated by L-cysteine (Acetium capsule). This led us to rational that by eliminating acetaldehyde in the stomach, L-cysteine could block (or reduce below the threshold levels) histamine liberation from the tissue mast cells and ECL cells in the stomach, thus arresting its multitude of functions, of which vasodilatation is critically involved in the migraine attack.
Objective: To validate the novel hypothesis that daily use of L-cysteine is an effective means to decrease the frequency of (or completely abort) the headache attacks in migraine patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-65 years male/female
- •subjects should report migraine attacks with the frequency of 2-8 times per month, and with less than 15 migraine days (NMD) per month. To be calculated as a separate attack, there should be at least 48h of freedom from headache between the two attacks of migraine.
- •migraine with or without aura has been present for at least 1 year prior to entering into the study
- •subjects to be enrolled should report the onset of their migraine before 50 years of age
排除标准
- •patients who meet the International Classification of Headache Disorders II criteria for medication overuse
- •patients who have taken anti-psychotics or anti-depressant medications during the previous 3 months
- •patients who abuse alcohol or other drugs
- •patients resistant to all acute migraine drugs optimally prescribed
- •potentially fertile and sexually active women who do not practise contraception
- •other acute or chronic pain disorders
- •severe psychiatric disease
- •infection
- •malignancy
- •short life expectancy
- •cardiovascular disease
- •cerebrovascular disease
- •uncontrolled hypertension
- •degenerative central nervous system diseases
- •pregnant and lactating women
- •regular users of Acetium capsules for other indications
- •persons suffering from renal dysfunction or cystinuria
研究组 & 干预措施
Acetium
Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months
干预措施: Acetium (Drug)
Placebo
Patient will administer placebo capsules twice a day for three months
干预措施: Placebo (Drug)
结局指标
主要结局
Number of migraine attacks (NMA) per evaluation interval
时间窗: 3 months
The frequency of headache attacks during the entire treatment period (3 months) is compared with the baseline frequencies, to disclose the differences in efficacy measures between the two arms.
次要结局
- Number of migraine days (NMD) per evaluation period(3 months)
